Gast ::
| Hauptseite > Publikationsdatenbank > Association of blood pressure, its treatment, and treatment efficacy with volume of white matter hyperintensities in the population-based 1000BRAINS Study > print |
| Hauptseite > Publikationsdatenbank > Association of blood pressure, its treatment, and treatment efficacy with volume of white matter hyperintensities in the population-based 1000BRAINS Study > print |
| 001 | 902561 | ||
| 005 | 20211130111101.0 | ||
| 024 | 7 | _ | |a 10.1161/HYPERTENSIONAHA.121.18135 |2 doi |
| 024 | 7 | _ | |a 2128/29062 |2 Handle |
| 024 | 7 | _ | |a altmetric:115063667 |2 altmetric |
| 024 | 7 | _ | |a pmid:34628935 |2 pmid |
| 024 | 7 | _ | |a WOS:000707194400040 |2 WOS |
| 037 | _ | _ | |a FZJ-2021-04360 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Gronewold, J. |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Association of blood pressure, its treatment, and treatment efficacy with volume of white matter hyperintensities in the population-based 1000BRAINS Study |
| 260 | _ | _ | |a Baltimore, Md. |c 2021 |b Williams & Wilkins |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1637322385_24320 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a White matter hyperintensities (WMHs) of presumed vascular origin are a frequent finding in cerebral magnetic resonance imaging of older people. They are attributed to small vessel disease and involved in the pathogenesis of cognitive decline. Since vascular risk factors, especially arterial hypertension, predispose to small vessel disease, we analyzed the association of systolic blood pressure (SBP), diastolic blood pressure (DBP), and antihypertensive medications with WMH volume in 560 participants of the 1000BRAINS study, drawn from the population-based Heinz Nixdorf Recall study (65.2±7.5 years; 51.4% men). Further, we analyzed treatment efficacy using a classification of 6 BP treatment groups defined by antihypertensive medication and level of BP: (1) untreated BP <120/<80 mm Hg, (2) untreated SBP 120 to 139 or DBP 80 to 89 mm Hg, (3) untreated BP ≥140 or ≥90 mm Hg, (4) treated BP <120/<80 mm Hg, (5) treated SBP 120 to 139 or DBP 80 to 89 mm Hg, and (6) treated BP ≥140 or ≥90 mm Hg. Median WMH volume (Q1–Q3) was 4.6 (3.0–7.8) cm3; mean±SD of SBP and DBP was 128.6±17.4 and 76.1±9.8 mm Hg. In multivariable linear regression models, continuous SBP (β=0.63 cm3 per 10 mm Hg [95% CI, 0.32–0.94]), DBP (0.64 cm3 per 5 mmHg [95% CI, 0.37–0.91]), and antihypertensive treatment (1.23 cm3 [95% CI, 0.14–2.23]) were significantly associated with WMH volume. Regarding treatment efficacy, only participants with hypertension despite treatment (treated BP ≥140 or ≥90 mm Hg) had significantly increased WMH volume (4.24 cm3 [2.36–6.13]) compared with normotension without treatment (untreated BP <120/<80 mm Hg). Our results suggest that WMHs represent a marker of advanced hypertension pathology. Hence, early treatment should prevent WMHs. |
| 536 | _ | _ | |a 5251 - Multilevel Brain Organization and Variability (POF4-525) |0 G:(DE-HGF)POF4-5251 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to DataCite |
| 700 | 1 | _ | |a Jokisch, M. |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Schramm, S. |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Jockwitz, Christiane |0 P:(DE-Juel1)145386 |b 3 |
| 700 | 1 | _ | |a Miller, Tatiana |0 P:(DE-Juel1)181023 |b 4 |
| 700 | 1 | _ | |a Lehmann, N. |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Moebus, S. |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Jöckel, K. H. |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Caspers, Svenja |0 P:(DE-Juel1)131675 |b 8 |
| 700 | 1 | _ | |a Hermann, D. M. |0 P:(DE-HGF)0 |b 9 |
| 773 | _ | _ | |a 10.1161/HYPERTENSIONAHA.121.18135 |0 PERI:(DE-600)2094210-2 |n 5 |p 1490-1501 |t Hypertension |v 78 |y 2021 |x 0194-911X |
| 856 | 4 | _ | |y Restricted |u https://juser.fz-juelich.de/record/902561/files/Gronewold_etal_Hypertension_2021.pdf |
| 856 | 4 | _ | |y Published on 2021-10-11. Available in OpenAccess from 2022-04-11. |z StatID:(DE-HGF)0510 |u https://juser.fz-juelich.de/record/902561/files/Gronewold_etal_Hypertension_2021_Postprint.docx |
| 909 | C | O | |o oai:juser.fz-juelich.de:902561 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)145386 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)181023 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)131675 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5251 |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-30 |
| 915 | _ | _ | |a Embargoed OpenAccess |0 StatID:(DE-HGF)0530 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b HYPERTENSION : 2019 |d 2021-01-30 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b HYPERTENSION : 2019 |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-01-30 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-30 |
| 915 | _ | _ | |a Allianz-Lizenz |0 StatID:(DE-HGF)0410 |2 StatID |d 2021-01-30 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-01-30 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-01-30 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-30 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-1-20090406 |k INM-1 |l Strukturelle und funktionelle Organisation des Gehirns |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-1-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|